Dear Sir/ Madam,

Sub: Qualified institutions placement of equity shares of face value Rs. 2 each (the “Equity Shares”) by Alembic Pharmaceuticals Limited (the “Company”) under the provisions of Chapter VI of Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended (the “SEBI ICDR Regulations”), and Sections 42 and 62 of the Companies Act, 2013, as amended, including the rules made thereunder (the “Issue”).

We wish to inform you that pursuant to the approval accorded by the board of directors of the Company (the “Board”), at its meeting held on 22nd May, 2020 and the special resolution passed on 22nd July, 2020 by the members of the Company, and the subsequent meeting of the Board held on 27th July, 2020, the Fund Raising Committee of the Board (the “Committee”) has, at its meeting held today i.e. 3rd August, 2020, inter alia, passed resolutions for the following:

a. Authorised the opening of the Issue today, i.e. 3rd August, 2020;

b. Approved and adopted the preliminary placement document dated 3rd August, 2020 in connection with the Issue; and

c. Approved the floor price for the Issue, based on the pricing formula prescribed under the SEBI ICDR Regulations.

We further wish to inform you that the ‘Relevant Date’ for the purpose of the Issue, in terms of Regulation 171 of the SEBI ICDR Regulations, is 3rd August, 2020 and accordingly the floor price in respect of the aforesaid Issue, based on the pricing formula as prescribed under Regulation 176(1) of the SEBI ICDR Regulations is Rs. 980.75 per Equity Share. Pursuant to Regulation 176(1) of the SEBI ICDR Regulations, the Company may offer a discount of not more than 5% on the floor price so calculated for the Issue. The issue price will be determined by the Company in consultation with the Book Running Lead Managers appointed for the Issue.

ALEMBIC PHARMACEUTICALS LIMITED
REGD. OFFICE : ALEMBIC ROAD, VADODARA - 390 003. • TEL : (0265) 2280550, 2280880 • FAX : (0265) 2281229
website : www.alembicpharmaceuticals.com • E-mail : alembic@alembic.co.in • CIN : L24230GJ2010PLC061123
The meeting of the Committee commenced at 4:30 p.m. and concluded at 5:00 p.m.

We request you to take the above on record and the same be treated as compliance under the applicable provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

Thanking you,

Yours faithfully,

For Alembic Pharmaceuticals Limited

Charandeep Singh Saluja
Company Secretary